Zometa 4 mg Injection
PDF Leaflet Revision Date: 16 August 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of tumour-induced hypercalcaemia and skeletal conditions in advanced malignancies.
Dosage (summary)
4 mg IV infusion over 15 mins every 3-4 weeks; hydration required.
Onset of Action / Duration
Onset: 2-3 months for skeletal conditions.
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to potential harm.
Key Drug Interactions
- Aminoglycosides
- Calcitonin
- Loop diuretics
- Nephrotoxic drugs
Contraindications
- Hypersensitivity to zoledronic acid
- Severe renal impairment
- Pregnancy
- Breastfeeding
Common side effects
- Renal impairment
- Bone pain
- Fever
- Nausea
- Hypocalcaemia
Counselling Points
- Maintain hydration
- Monitor for renal function
- Report any jaw pain or dental issues
- Avoid invasive dental procedures
Serious warnings
- Renal function monitoring required
- Risk of osteonecrosis of the jaw
- Acute phase reaction
Important Disclaimer
The Zometa 4 mg Injection professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
